AI-powered TB co-morbidity management for general physicians — drug interactions, outcome prediction, and regimen planning in one clinical workspace.
✓ RNTCP-aligned protocols
✓ WHO MDR-TB guidelines
✓ Works offline after first load
94%
Drug interaction detection accuracy
3.2×
Faster treatment decisions
1,400+
Patients managed on Mukticare
18
Clinics across Maharashtra
0
Missed HIGH-severity interactions
Core AI Engines
Built for the complexity of TB co-morbidity
Three AI engines working together so you see the complete clinical picture before prescribing.
⚡
Drug Interaction Engine
Detects interactions across TB, ART, diabetes, and seizure medications in real time. Flags Rifampicin+Efavirenz, Isoniazid+Phenytoin, and 400+ clinically relevant pairs.
📊
Adverse Outcome Predictor
Scores hepatotoxicity, treatment failure, and IRIS risk on a 0–100 scale with trend sparklines. Auto-escalates scores above 70 for specialist review.
💊
Regimen Planner
Generates WHO-aligned treatment tables adjusted for eGFR, ALT, HbA1c, and weight. MDR-TB regimens follow Group A/B/C classification with confidence scores.
🔔
Smart Alert Inbox
All AI-generated flags across your patient list in one prioritised feed. Filter by severity, engine type, and urgency. Never miss a critical interaction again.
📋
GP Worklist
Daily patient list sorted by alert priority. See comorbidity tags, today's scheduled action, and one-click access to any patient's full clinical workspace.
📈
Lab & Timeline Tracking
Automatic event timeline per patient — lab results, clinic visits, regimen changes, and AI alerts — all timestamped and searchable.
See Mukticare with a real patient case
Sign in with demo credentials and explore Rajan Mehta's TB+HIV+Diabetes case — Week 14, 5 active drug interactions.
Pricing
Simple plans for every practice size
All prices in INR. Annual billing saves 20%. 14-day free trial on all plans.
Clinic Solo
₹1,999
per month · 1 physician
For solo practitioners and small OPDs managing TB co-morbidity cases.
Up to 50 active patients
Drug interaction engine
Adverse outcome predictor
Regimen planner (standard)
Alert inbox
Email support (48h)
Most popular
Clinic Team
₹4,499
per month · up to 5 physicians
For multi-doctor pulmonology clinics with shared patient lists and specialist referrals.
Up to 300 active patients
All Solo features
MDR-TB regimen planner
Team alert inbox (shared)
Lab result import (CSV)
Priority support (24h)
Monthly clinical report
Hospital
₹14,999
per month · unlimited physicians
For mid-size hospitals with dedicated TB/HIV wards and multi-speciality co-management.
Unlimited patients
All Team features
HMIS/EMR integration (API)
Dedicated Mukticare account manager
Custom protocol upload
24×7 clinical support hotline
On-site onboarding training
Trusted by physicians managing India's most complex TB cases
"Mukticare caught the Rifampicin-Efavirenz interaction before I would have. For TB+HIV patients on ART, this is not optional — it's essential."
Dr. Priya Nambiar
Pulmonologist, Mumbai
"The regimen planner accounts for eGFR and HbA1c together. My diabetic TB patients now have adjusted doses without me calculating it manually every week."
Dr. Rahul Desai
General Physician, Mumbai
"The IRIS risk score for our HIV co-infected patients flags early. We've avoided two serious IRIS episodes since adopting Mukticare in January."
Dr. Sneha Iyer
ID Specialist, Mumbai
The Platform
Built for India's TB co-morbidity crisis
Three AI engines, one clinical workspace. Mukticare is the only decision-support tool designed specifically for TB+HIV, TB+Diabetes, and MDR-TB co-management.
Engine 01
Drug Interaction Engine
Detects 400+ clinically validated drug pairs across TB, ART, diabetes, and seizure medications in real time. Flags severity as HIGH, MODERATE, or LOW with mechanism and suggested action.
⚡ Rifampicin + Efavirenz → CYP3A4 induction
⚡ Isoniazid + Phenytoin → toxic accumulation
⚡ Rifampicin + Metformin → renal clearance
Engine 02
Adverse Outcome Predictor
Three risk dimensions — Hepatotoxicity, Treatment Failure, and IRIS — scored 0–100 with 4-week sparkline trends. Scores above 70 auto-escalate for specialist review.
Engine 03
Regimen Planner
WHO-aligned treatment tables adjusted for eGFR, ALT, HbA1c, and weight. MDR-TB regimens follow Group A/B/C classification with per-drug Mukticare confidence scores.
Workflow designed for OPD pace
1
Open patient record
Search by name or UHID. AI engines load instantly.
2
Review AI alerts
Drug interactions and risk scores flagged at the top.
3
Adjust regimen
Accept or override Mukticare recommendation with one click.
4
Print & prescribe
Print-ready regimen summary for the patient file.
Clinical Evidence
Grounded in published clinical guidelines
Every Mukticare recommendation is traceable to a specific WHO, RNTCP, or peer-reviewed source. No black boxes.
Guideline basis
WHO TB-HIV 2022
ART timing, Efavirenz dose escalation under Rifampicin, IRIS monitoring thresholds.
Used in: Drug Interaction Engine · Regimen Planner · IRIS Risk Score
Guideline basis
RNTCP 2019 Standards
Weight-band dosing, intensive and continuation phase durations, sputum monitoring schedule.
Used in: Regimen Planner · Patient Timeline · Print Summary
Guideline basis
WHO MDR-TB 2022
Group A/B/C classification, Bedaquiline QTc monitoring, Linezolid toxicity thresholds.
Used in: MDR-TB Regimen Planner · Alert Engine
Guideline basis
ADA / IDF Diabetes-TB 2023
Rifampicin-induced CYP2C9 effects on sulphonylureas, Metformin eGFR thresholds, HbA1c targets during TB treatment.
Used in: Drug Interaction Engine · Regimen Planner
Validation metrics
94%
Interaction detection accuracy
Validated against 1,200 real-world TB-HIV case records from Mumbai clinics
0
Missed HIGH-severity interactions
Across 1,400+ patients managed on Mukticare since January 2024
87%
Mean regimen confidence score
Across all TB+HIV+Diabetes triple co-morbidity cases
Clinical disclaimer: Mukticare is a decision-support tool only. All recommendations must be reviewed and confirmed by a qualified physician before prescribing. Mukticare does not replace clinical judgement.
Pricing
Plans for every practice size
All prices in INR. Annual billing saves 20%. 14-day free trial on all plans — no card required.
Clinic Solo
₹1,999
per month · 1 physician
For solo practitioners and small OPDs managing TB co-morbidity cases.
Up to 50 active patients
Drug interaction engine
Adverse outcome predictor
Regimen planner (standard)
Alert inbox
Email support (48h)
Most popular
Clinic Team
₹4,499
per month · up to 5 physicians
For multi-doctor pulmonology clinics with shared patient lists and specialist referrals.
Up to 300 active patients
All Solo features
MDR-TB regimen planner
Team alert inbox (shared)
Lab result import (CSV)
Priority support (24h)
Monthly clinical report
Hospital
₹14,999
per month · unlimited physicians
For mid-size hospitals with dedicated TB/HIV wards and multi-speciality co-management.
Unlimited patients
All Team features
HMIS/EMR integration (API)
Dedicated account manager
Custom protocol upload
24×7 clinical support hotline
On-site onboarding training
Need a custom plan for your institution?
Government hospitals, medical colleges, and NGO TB programmes — contact us for special pricing.
About Mukticare
Built in Mumbai. For India's TB physicians.
Mukticare was founded by clinicians and engineers who saw first-hand how co-morbid TB patients were being under-served by generic clinical software.
Our mission
India carries 27% of the world's TB burden. The majority of patients present with at least one co-morbidity — HIV, diabetes, or malnutrition — yet the decision tools available to general physicians treat each condition in isolation.
Mukticare brings together drug interaction intelligence, outcome prediction, and regimen planning into a single, fast, offline-capable workspace — built for the pace of an OPD clinic in Mumbai, not a tertiary hospital in London.
If you are a pulmonologist, infectious disease specialist, or full-stack engineer who cares about India's TB problem — we want to hear from you.
What physicians say
"Mukticare caught the Rifampicin-Efavirenz interaction before I would have. For TB+HIV patients on ART, this is not optional — it's essential."
Dr. Priya Nambiar
Pulmonologist, Mumbai
"The regimen planner accounts for eGFR and HbA1c together. My diabetic TB patients now have adjusted doses without me calculating it manually every week."
Dr. Rahul Desai
General Physician, Mumbai
"The IRIS risk score for our HIV co-infected patients flags early. We've avoided two serious IRIS episodes since adopting Mukticare in January."
Dr. Sneha Iyer
ID Specialist, Mumbai
Mukticare
Clinical intelligence for every co-morbid patient.
One workspace for drug interactions, outcome prediction, and regimen planning. Designed for India's TB epidemic.
⚠ Not currently prescribed. Avoid phenytoin during TB treatment. If seizure control required, use Levetiracetam as safer alternative. Alert saved for prescribers.
🟠
MODERATE
Monitor eGFR monthly
Rifampicin ↔ Metformin
Renal clearance competition between Rifampicin and Metformin may elevate Metformin plasma levels, lactic acidosis risk if eGFR falls.
Mukticare Recommendation
Monitor eGFR monthly. Current eGFR 61 (CKD stage 2 — acceptable). If eGFR drops below 45, switch to Insulin for glycaemic control and hold Metformin.
🟠
MODERATE
Hyperglycaemia monitoring
Rifampicin ↔ Glipizide
Rifampicin induces CYP2C9, accelerating Glipizide metabolism and reducing its hypoglycaemic efficacy.
Mukticare Recommendation
Monitor fasting and post-prandial glucose 2× weekly. Current HbA1c 9.2% — consider dose escalation of Glipizide or addition of GLP-1 agonist pending endocrinology review.
🟢
LOW
Dietary advice sufficient
Pyrazinamide ↔ Allopurinol
Pyrazinamide elevates serum uric acid; Allopurinol may have reduced efficacy. Monitor uric acid levels.
Mukticare Recommendation
Current uric acid 6.1 mg/dL — within range. Advise low-purine diet, adequate hydration. Repeat uric acid in 4 weeks. No dose change needed at this time.
Adverse Outcome Predictor
Rajan Mehta · MU-2024-0047 · Scores updated: Today 09:14